Quasispecies nature of hepatitis C virus and response to alpha interferon: Significance as a predictor of direct response to interferon

Journal of Hepatology

Volumn 26, Issue 1, 1997, Pages 6-13

  Toyoda, Hidenori ^a   Kumada, Takashi ^a   Nakano, Satoshi ^a   Takeda, Isao ^a   Sugiyama, Keiichi ^a   Osada, Toshimasa ^a   Kiriyama, Seiki ^a   Sone, Yasuhiro ^a   Kinoshita, Moritoshi ^b   Hadama, Toru ^b  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

direct response to interferon; hepatitis C virus; interferon; predictor of response; quasispecies; relapse

Indexed keywords

ALPHA INTERFERON;

ADULT; ARTICLE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0031024940     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80002-5     Document Type: Article

References (59)

1. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA. Treatment of chronic non-A, non-B, hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 315:1986;1575-1578.
2. Thomsom BJ, Doran M, Lever AML, Webster ABD. Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy. Lancet. i:1987;539-541.
3. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr., Perillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschivitz C, Ortego TJ, Gibas A. The Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter randomized controlled trial. N Engl J Med. 321:1989;1501-1506.
4. Di Bisceglie Am, Martin P, Kassiandies C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH. Recombinant interferon alpha therapy for chronic hepatitis C. N Engl J Med. 321:1989;1506-1510.
5. Kakumu S, Arao M, Yoshioka K, Hayashi H, Kusakabe A, Hirofuji H, Kawabe M. Recombinant human-interferon therapy for chronic non-A, non-B hepatitis: second report. Am J Gastroenterol. 85:1989;655-659.
6. Omata M, Ito Y, Yokusuka O, Imazeki F, Uchiumiu K, Takano S, Hosoda K, Ohto M. Histological changes of the liver by treatment of chronic non-A, and non-B hepatitis with recombinant leukocyte interferon alpha: comparison with histological changes in chronic hepatitis B. Dig Dis Sci. 34:1989;330-337.
7. Jacyna MR, Brooks MG, Loke RHT, Main J, Murray-Lyon IM, Thomas HC. Randomized controlled trial of interferon alpha (lymphoblastoid interferon) in chronic non-A, non-B hepatitis. Br Med J. 298:1989;80-82.
8. Causse X, Goginot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud J-P, Fontagnes T, Albrecht J, Meschievitz C, Trepo C. Comparison of 1 or 3 MU interferon alpha-2b and placebo in patients with chronic non-A, Non-B hepatitis. Gastroenterology. 101:1991;497-502.
9. Carreno V, Marriott E, Quiroga JA. Other approaches to the treatment of chronic viral hepatitis. J Hepatol. 17:1993;S127-S129.
10. Shindo M, Di Bisceglie A, Cheung L, Shih JW-K, Cristiano K, Feinsteon SM, Hoofnagle JH. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med. 115:1991;700-704.
11. Schlauder GG, Leverenz GJ, Mattson L, Weiland O, Mushahwar IK. Detection of hepatitis C viral RNA by the polymerase chain reaction in serum of patients with postransfusion non-A, non-B hepatitis. J Virol Methods. 37:1992;189-200.
12. Marcellin P, Pouteau M, Boyer N, Castelnau C, Erlinger S, Benhamou JP. Retreatment with recombinant interferon-α in patients with chronic hepatitis C. J Infect Dis. 167:1993;780.
13. Marriott E, Quiroga JA, Carreno V. Retreatment of chronic hepatitis C with interferon-α J Infct Dis. 166:1992;1200-1201.
14. Hoofnagle JH, Di Bisceglie AM. Treatment of chronic type C hepatitis with alpha interferon. Semin Liver Dis. 9:1989;259-263.
15. Davis GL. Recombinant α-interferon treatment of non-A, non-B (type C) hepatitis: review of studies and recommendations for treatment. J Hepatol. 11:1990;S72-S77.
16. Weiland O, Schvarcz R, Wejstal R, Norkrans G, Fryden A. Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alpha-2b; Swedish experience. J Hepatol. 11:1990;S57-S62.
17. Causse X, Godinot H, Ouzon D. Recombinant alpha interferon for chronic non-A, non-B hepatitis: optimal dose and factors associated with favourable response. J Hepatol. 10:1989;643. [abstract].
18. Schvarcz R, Weiland O, Wejstal R, Norkrans G, Fryden A, Foberg U. A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies. Scand J Infect Dis. 21:1989;617-625.
19. Hess G. Treatment of chronic hepatitis C. J Hepatol. 12:1991;S17-S20.
20. Yamada G, Takahashi M, Tsuju T, Yoshizawa H, Okamoto H. Quantitative HCVRNA and effect of interferon therapy in chronic hepatitis C. Dig Dis Sci. 37:1992;1926-1927.
21. Hagiwara H, Hayashi N, Mita E, Tekehara T, Kasahara A, Fusamoto H, Kamada T. Quantitative analysis of hepatitis C virus in serum during interferon alpha therapy. Gastroenterology. 104:1993;877-883.
22. Lau JYN, Davis GL, Kniffen J, Qian K-P, Urdea MS, Chan CS, Mizokami M, Nuewald PD, Wilber JC. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 341:1993;1501-1504.
23. Kanai K, Kato M, Okamoto H. HCV genotype in chronic hepatitis C and response to interferon. Lancet. 339:1992;1543.
24. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, Shibata M, Morishima T. Detection of hepatitis C virus by polymerase chain reaction and response to interferon alfa therapy; relation to genotypes of hepatitis C virus. Hepatology. 16:1992;293-299.
25. Takada N, Takase S, Takada A. Effects of genotypes of hepatitis C virus on interferon treatment for chronic type C hepatitis. Gastroenterol Jpn. 28:1993;268-275.
26. Takase S, Takada N, Sawada M, Takada A, Okanoue T, Yano M, Yatsuhashi H. Effects of interferon treatment for chronic type C liver diseases with different hepatitis C virus genotypes: a cooperative study in three hospitals. Int Hepatol Commun. 1:1993;321-325.
27. Matsumoto A, Tanaka E, Suzuki T, Ogata H, Kiyosawa K. Viral and host factors that contribute to efficacy of interferon-α 2a therapy in patients with chronic hepatitis C. Dig Dis Sci. 39:1994;1273-1280.
28. Okada S, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to inteferon therapy in viremic patients. Hepatology. 16:1992;619-624.
29. Kanazawa Y, Hayashi N, Mita E, Li T, Hagiwara H, Kasahara A, Fusamoto H, Kamada T. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology. 20:1994;1121-1130.
30. Moribe T, Hayashi N, Kanazawa Y, Mita E, Fusamoto H, Negi M, Kaneshige T, Igimi H, Kamada T, Uchida K. Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. Gastroenterology. 108:1995;789-795.
31. Koizumi K, Enomoto N, Kurosaki M, Murakami T, Izumi N, Marumo F, Sato C. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology. 22:1995;30-35.
32. Shibata M, Morishima T, Kudo T, Maki T, Maki S, Nagai Y. Serum hepatitis C virus sequences in port-transfusion non-A, non-B hepatitis. Blood. 77:1991;1157-1160.
33. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 19:1994;1513-1520.
34. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y, Mayumi M. Typing hepatitis C virus by polymerase chain reaction with type-specific primers. An application to clinical surveys and tracing infection sources. J Gen Virol. 73:1992;673-679.
35. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT, Chan S-W, Chayama K, Chen D-S, Choo Q-L, Colombo M, Cuypers HTM, Date T, Dusheiko GM, Esteban JI, Fay O, Hadziyannis SJ, Han J, Hatzakis A, Holmes EC, Hotta H, Houghton M, Irvine B, Kohara M, Kolberg JA, Kou G, Lau JYN, Lelie PN, Maertens G, McOmish F, Miyamura T, Mizokami M, Nomoto A, Prince AM, Reesink HW, Rice C, Roggendorf M, Schalm SW, Shikata T, Shimotohno K, Stuyver L, Trepo C, Weiner A, Yap Pl, Urdea M. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology. 19:1994;1321-1324.
36. Sanchez-Pescador R, Sheridan PJ, Detmer JJ, Hunt WP, Chan CS, Wright T, Okano A, Wilber JC, Neuwald PD, Urdea MS. Quantitative detection of HCVRNA in human sera using a chemoluminescent signal amplification oligonucleotide probe assay. Hepatology. 16:1992;588. [Abstract].
37. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics. 5:1989;874-879.
38. Enomoto N, Kurosaki M, Tanaka Y, Marumo F, Sato C. Fluctuation of hepatitis C virus quasispecies in persisitent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. J Gen Virol. 75:1994;1361-1369.
39. Makino R, Yazyu H, Kishimoto Y, Sekiya T, Hayashi K. FSSCP: Fluorescence-based polymerase chain reaction -single-strand conformation polymorphism (PCR-SSCP) analysis. PCR Methods Applic. 2:1992;10-13.
40. Kinoshita M, Hadama T, Yamakawa Y, Shin S, Chayama K, Kumada H. A detection method for mutations in the hypervariable region of HCV-RNA using the fluorescence-SSCP and -sequence analysis. Hepatology. 20:1994;365A. [Abstract].
41. Fried MW, Hoofnagle JH. Therapy of chronic hepatitis C. Semin Liver Dis. 15:1995;82-91.
42. Steinhauer DA, Holland JJ. Rapid evolution of RNA viruses. Ann Rev Microbiol. 41:1987;409-433.
43. Holland JJ, de la Torre JC, Steinhauer DA. RNA virus populations as quasipecies. Curr Topics in Microbiol and Immunol. 176:1992;1-20.
44. Domingo E, Martinez-Salas E, Sobrino F, de la Torre JC, Portela A, Ortin J, Lopez-Galindez C, Perez-Brena P, Villanueva N, Najera R, VandePol S, Steinhauer D, DePolo N, Holland J. The quasispecies (extremely heterogeneous) nature of viral RNA genone populations: biological revelance - a review. Gene. 40:1985;1-40.
45. Bilsel PA, Nichol ST. Polymerase errors accumulating during natural evolution of the glycoprotein gene of vesicular stomatitis virus Indiana serotype isolates. J Virol. 64:1990;4873-4883.
46. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA. 87:1990;9524-9528.
47. Takamizawa A, Mori C, Fuke I, Manabe S, Murakami S, Fujita J, Onishi E, Andoh T, Yoshida I, Okayama H. Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol. 65:1991;1105-1113.
48. Choo Q-L, Richman KH, Han JH, Berger K, Lee C, Dong C, Gallegos C, Coit D, Medina-Selby A, Barr PJ, Weiner AJ, Bradley DW, Kuo G, Houghton M. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA. 88:1991;2451-2455.
49. Oshima M, Tsuchiya M, Yagasaki M, Orita T, Hasegawa M, Tomonoh K, Kojima T, Hirata Y, Yamamoto O, Sho Y, Maeda E, Arima T. cDNA clones of Japanese hepatitis C virus genomes derived from a single patient show sequence heterogeniety. J Gen Virol. 72:1991;2805-2809.
50. Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, Guardia J, Gomez J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes; quasispecies nature of HCV genome distribution. J Virol. 66:1992;3225-3229.
51. Murakawa K, Esumi M, Kato T, Kambara H, Shikata T. Heterogeneity within the nonstructural protein 5-encoding region of hepatitis C viruses from a single patients. Gene. 117:1992;229-232.
52. Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, Bonino F, Crawford K, Marion CD, Crawford KA, Brunetto M, Barr PJ, Miyamura T, McHutchinson J, Houghton M. Evidence for immune selection of hepatitis C virus putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci USA. 89:1992;3468-3472.
53. Zonaro A, Ravaggi A, Puoti M, Kremsdorf D, Albertini A, Cariani E. Differential pattern of sequence heterogeneity in the hepatitis C virus E1 and E2/NS1 proteins. J Hepatol. 21:1994;858-865.
54. Honda M, Kaneko S, Sakai A, Unoura M, Murakami S, Kobayashi K. Degree of diversity of hepatitis C virus quasispecies and progression of liver disease. Hepatology. 20:1994;1144-1151.
55. Tsubota A, Chayama K, Ikeda K, Arase Y, Koida I, Saitoh S, Hashimoto M, Iwasaki S, Kobayashi M, Kumada H. Factors predictive of response to interferon-α therapy in hepatits C virus infectin. Hepatology. 19:1994;1088-1094.
56. Orito E, Mizokami M, Nakamo T, Terashima H, Nojiri O, Sakakibara K, Mizuno M, Ogino M, Nakamura M, Matsumot Y, Miyata K, Lau JYN. Serum hepatiti s C virus RNA levels as a predictor of subsequent response to interferon-α therapy in Japanese patients with chronic hepatitis C. J Med Virol. 44:1994;410-414.
57. Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, Kiriyama S, Orito E, Mizokami M. Comparison of serum hepatitis C virus RNA concentration by branced DNA probe assay with competitive reverse transcription polymerase chain reaction as a predictor of response to interferon-α therapy in chronic hepatitis C patients. J Med Virol. 48:1996;354-359.
58. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. J Clin Invest. 96:1995;224-230.
59. Yuki N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Oshita M, Katayama K, Fusamoto H, Kamada T. Pretreatment viral load and response to prolonged interferon-α course for chronic hepatitis C. J Hepatol. 22:1995;457-463.